TScan Therapeutics (TCRX) Stock Price, News & Analysis

Company Overview

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $2.91 to $3.15
• 50-Day Range: $2.85 to $5.94
• 52-Week Range: $2.60 to $9.69
• Volume: 394,876 shs
• Average Volume: 263,199 shs
• Market Capitalization: $158.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.25
• Consensus Rating: Buy

TScan Therapeutics Stock Analysis - MarketRank™

TScan Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 541st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TScan Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.12) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TScan Therapeutics is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TScan Therapeutics is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TScan Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.34% of the float of TScan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TScan Therapeutics has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in TScan Therapeutics has recently increased by 0.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TScan Therapeutics does not currently pay a dividend.

Dividend Growth

TScan Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.34% of the float of TScan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TScan Therapeutics has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in TScan Therapeutics has recently increased by 0.87%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.21

News Sentiment

TScan Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for TCRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, TScan Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,560.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.76% of the stock of TScan Therapeutics is held by insiders.

Percentage Held by Institutions

82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TCRX Stock Analysis - Frequently Asked Questions

How have TCRX shares performed this year?

TScan Therapeutics' stock was trading at $5.83 at the start of the year. Since then, TCRX shares have decreased by 49.1% and is now trading at $2.97.
View the best growth stocks for 2024 here.

How were TScan Therapeutics' earnings last quarter?

TScan Therapeutics, Inc. (NASDAQ:TCRX) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.03. The business earned $1.05 million during the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative trailing twelve-month return on equity of 58.72%.

When did TScan Therapeutics IPO?

TScan Therapeutics (TCRX) raised $100 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

Who are TScan Therapeutics' major shareholders?

Top institutional shareholders of TScan Therapeutics include Great Point Partners LLC (1.92%), Geode Capital Management LLC (1.84%), Checkpoint Capital L.P. (1.56%) and State Street Corp (1.43%). Insiders that own company stock include Lynx1 Capital Management Lp, Timothy J Barberich, Barbara Klencke, Brian M Silver and Zoran Zdraveski.
View institutional ownership trends.

How do I buy shares of TScan Therapeutics?

Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of TScan Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TScan Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCRX
• CUSIP: N/A
• CIK: 1783328
• Web: www.tscan.com
• Phone: 857-399-9500
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.25
• High Stock Price Target: $15.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +278.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-89,220,000.00
• Net Margins: -1,188.88%
• Pretax Margin: -1,188.88%
• Return on Equity: -58.72%
• Return on Assets: -36.02%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 9.56
• Quick Ratio: 9.56

Sales & Book Value

• Annual Sales: $21.05 million
• Price / Sales: 7.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.15 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 53,370,000
• Free Float: 51,898,000
• Market Cap: $158.51 million
• Optionable: Not Optionable
• Beta: 0.79